DISCOVERY. INNOVATION. GLOBAL HEALTH.

Advancing migrasome science from discovery to transformative healthcare solutions.

Bringing original biological discoveries from China to patients worldwide

ABOUT MIGRASOME

About Migrasome Therapeutics

Migrasome Therapeutics builds on the original discovery of migrasomes to develop new diagnostic and therapeutic approaches, with the aim of benefiting patients worldwide.

Founded in April 2022 and headquartered in Beijing's Changping Life Science Park, Migrasome Therapeutics (Beijing) Co., Ltd. is a biotechnology company built on original migrasome science and focused on translating life-science discoveries into innovative healthcare technologies.

Professor Li Yu's team first discovered and named the migrasome. The team systematically revealed the roles of migrasomes in intercellular communication, tissue development, immune regulation, and disease processes, providing the scientific basis for Migrasome's technology development.

Migrasome Therapeutics brings together migrasome science, modern molecular biology, drug discovery, and engineering. It is developing a healthcare technology platform to study major disease mechanisms and develop diagnostics and therapeutics, while exploring migrasomes for disease detection and precision drug delivery to address unmet clinical needs.

SCIENTIFIC FOUNDER

Scientific Founder

Professor Li Yu

Professor at Tsinghua University and doctoral supervisor

Recipient of the National Science Fund for Distinguished Young Scholars, Chang Jiang Distinguished Professor, and New Cornerstone Investigator. As the discoverer and namer of migrasomes, Professor Li Yu's team first reported and named this new organelle in Cell Research in 2014. Over the past decade, the team has published extensively in leading journals including Science, Cell, and Nature Cell Biology, systematically revealing the core roles of migrasomes in intercellular communication, mitochondrial quality control, and the coagulation system, laying the theoretical foundation for migrasome-targeted drug development.

CORE TEAM

Core team

The team brings together experience from universities, research institutions, and industry, combining scientific research with commercialization to develop migrasome applications.

Chairman & Legal Representative

Yu Ting

Senior investor with more than 30 years of experience in commodities trading, derivatives, and secondary-market trading.

Co-founder

Luo Chuan

Bachelor's degree from Sichuan University; co-founder of the listed company Sifang Jingchuang; more than 20 years of company operations and commercialization experience.

Chief Operating Officer

Dr. Wanqiu Hu

PhD from EPFL; more than ten years of R&D and company-management experience; formerly President of Creative Biolabs and an R&D scientist at AC Immune.

Chief Technology Officer

Dr. Chen Dai

Bachelor's degree from Tsinghua University and PhD from the University of Notre Dame; recipient of the Changju Program Innovative Young Talent award. Previously served as an R&D scientist at companies including BeiGene and Hengrui, with many years of experience in innovative drug and delivery-system R&D.

Chief Scientific Officer

Dr. Xinfeng Hou

PhD through the National Institute of Biological Sciences, Beijing and Peking University; formerly Principal Research Scientist at BeiGene, with years of biopharmaceutical R&D experience.

RESEARCH ACHIEVEMENTS

Research outcomes

Building on the original discovery of migrasomes, the company advances research into fundamental mechanisms and develops research methods and translational tools.

Original discovery and naming of migrasomes
Professor Li Yu's team first discovered and named migrasomes, establishing the scientific foundation for subsequent translation.
Formation mechanisms and biological functions
Ongoing work explores migrasome formation, intercellular communication, tissue development, and disease-related functions.
Research methods and translational tools
The company is building its capabilities in research methods, reagents, detection tools, and engineering platforms.

QUALIFICATIONS & PATENTS